Wellumio is expanding its global footprint by launching a new subsidiary in California, USA—a strategic move that, according to the company, lays the groundwork for planned USA-based clinical trials to validate its innovative Axana device and accelerate its mission to bring this portable, life-saving technology to frontline stroke teams nationwide.
Following their initial presentation earlier this year, two randomised controlled trials (RCTs) indicating positive outcomes with middle meningeal artery (MMA) embolisation in chronic subdural haematoma (cSDH) patients were discussed in greater detail at the recent LINNC Paris meeting (3–5 June, Paris, France).
In an official statement, the Society of Neurolnterventional Surgery (SNIS) has acknowledged middle meningeal artery (MMA) embolisation as a beneficial adjunctive treatment for chronic subdural haematoma (SDH).
At the 2024 International Stroke Conference (ISC; 7–9 February, Phoenix, USA), Adam Arthur (University of Tennessee Health Science Center, Memphis, USA)—co-principal investigator for STEM alongside David Fiorella (Stony Brook Cerebrovascular Center, Stony Brook, USA)—relayed that MMA embolisation with the Squid liquid embolic system (Balt) was deemed superior to standard management on the basis of the… Read More
In a guest piece for NeuroNews, Thomas Devlin (Chattanooga, USA) and Michelle Luffey advise the community on how best to navigate the transition from primary stroke centres (PSCs) to comprehensive stroke centres (CSCs) and, in doing so, provide stroke patients with the highest possible level of care.
